All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
Immune-based therapies in multiple myeloma (MM) include agents such as chimeric antigen receptor (CAR) T cells, as well as bispecific antibody therapies. These novel agents are often associated with high initial response rates compared with standard therapies, yet most patients go on to experience a relapse. In an effort to improve duration of response, dual antigen targeting and trispecific antibodies are currently being investigated in MM.1
Here we summarize a presentation by Sham Mailankody1 from the International Myeloma Society’s 5th Immune Effector Cell Therapies in Multiple Myeloma Workshop, 2024, on antigen-targeting CAR T cells and antibody therapies in MM.
Figure 1. Methods of dual antigen-targeting in MM*
CAR, chimeric antigen receptor; TCE, T-cell engager.
Created with BioRender.com.
*Adapted from Mailankody.1
Figure 2. Response rates from RedirecTT-1 in A response-evaluable patients and B patients with EMD*
CR, complete response; PR, partial response; Q2W, once every 2 weeks; sCR, stringent complete response; tal, talquetamab; tec, teclistamab; VGPR, very good partial response.
*Adapted from Mailankody.1
Key learnings1 |
---|
|
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox